Published in Vaccine on September 20, 2006
Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis (2009) 2.36
Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type. J Clin Microbiol (2009) 1.48
Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS One (2007) 1.26
Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol (2007) 1.04
Effect of vaccination on Bordetella pertussis strains, China. Emerg Infect Dis (2010) 0.98
SNP-based typing: a useful tool to study Bordetella pertussis populations. PLoS One (2011) 0.93
Comparison of culture and real-time PCR for detection of Bordetella pertussis isolated from patients in Iran. Iran J Microbiol (2013) 0.85
Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection. Biomed Res Int (2014) 0.76
Genetic Variation of Bordetella pertussis in Austria. PLoS One (2015) 0.76
Genetic Profile Variation in Vaccine Strains and Clinical Isolates of Bordetella pertussis Recovered from Iranian Patients. Avicenna J Med Biotechnol (2014) 0.76
Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis (2009) 2.36
Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis (2010) 2.20
Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J (2005) 2.06
Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis (2007) 1.77
Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio (2014) 1.76
Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis (2011) 1.74
Bordetella holmesii DNA is not detected in nasopharyngeal swabs from Finnish and Dutch patients with suspected pertussis. J Med Microbiol (2006) 1.69
Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland. Clin Vaccine Immunol (2012) 1.50
Release of canine parvovirus from endocytic vesicles. Virology (2003) 1.41
Bordetella pertussis strain variation and evolution postvaccination. Expert Rev Vaccines (2009) 1.38
Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect (2005) 1.36
Reference system for characterization of Bordetella pertussis pulsed-field gel electrophoresis profiles. J Clin Microbiol (2004) 1.35
Factors contributing to pertussis resurgence. Future Microbiol (2008) 1.35
Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants? J Infect Dis (2003) 1.29
Strain variation among Bordetella pertussis isolates in finland, where the whole-cell pertussis vaccine has been used for 50 years. J Clin Microbiol (2005) 1.28
Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics (2008) 1.26
Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS One (2007) 1.26
Titration-free massively parallel pyrosequencing using trace amounts of starting material. Nucleic Acids Res (2010) 1.25
Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol (2005) 1.23
Multiple-primer DNA sequencing method. Electrophoresis (2003) 1.21
Pertussis vaccination in infancy lowers the incidence of pertussis disease and the rate of hospitalisation after one and two doses: analyses of 10 years of pertussis surveillance. Vaccine (2011) 1.11
Bordetella pertussis, Finland and France. Emerg Infect Dis (2006) 1.05
Rhinovirus infections in children: a retrospective and prospective hospital-based study. J Med Virol (2009) 1.05
Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol (2007) 1.04
Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift? BMC Genomics (2010) 1.04
The seroepidemiology of immunoglobulin G antibodies against pertussis toxin in China: a cross sectional study. BMC Infect Dis (2012) 1.03
Bordetella pertussis isolates in Finland: serotype and fimbrial expression. BMC Microbiol (2008) 1.02
Differences in the genomic content of Bordetella pertussis isolates before and after introduction of pertussis vaccines in four European countries. Infect Genet Evol (2011) 1.01
Clinical outcome of pertussis in Sweden: association with pulsed-field gel electrophoresis profiles and serotype. APMIS (2007) 0.98
Effect of vaccination on Bordetella pertussis strains, China. Emerg Infect Dis (2010) 0.98
Ultrasonography after the first febrile urinary tract infection in children. Eur J Pediatr (2006) 0.97
Titration-free 454 sequencing using Y adapters. Nat Protoc (2011) 0.97
Nasopharyngeal bacterial colonization and gene polymorphisms of mannose-binding lectin and toll-like receptors 2 and 4 in infants. PLoS One (2011) 0.96
Genomic stability over 9 years of an isoniazid resistant Mycobacterium tuberculosis outbreak strain in Sweden. PLoS One (2011) 0.96
Microarray analysis of response of Salmonella during infection of HLA-B27- transfected human macrophage-like U937 cells. BMC Genomics (2010) 0.93
European Sero-Epidemiology Network 2: standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparations. Vaccine (2008) 0.93
SNP-based typing: a useful tool to study Bordetella pertussis populations. PLoS One (2011) 0.93
Use of monoclonal antibodies to serotype Bordetella pertussis isolates: comparison of results obtained by indirect whole-cell enzyme-linked immunosorbent assay and bacterial microagglutination methods. J Clin Microbiol (2005) 0.93
Bordetella pertussis infection is common in nonvaccinated infants admitted for bronchiolitis. Pediatr Infect Dis J (2010) 0.92
Seroprevalence of antibodies to pertussis and diphtheria among healthy adults in China. J Infect (2011) 0.91
Comparison of total white blood cell count and serum C-reactive protein levels in confirmed bacterial and viral infections. J Pediatr (2006) 0.90
Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis (2004) 0.89
Rapid typing of Bordetella pertussis pertussis toxin gene variants by LightCycler real-time PCR and fluorescence resonance energy transfer hybridization probe melting curve analysis. J Clin Microbiol (2002) 0.89
Pertussis before and after the introduction of acellular pertussis vaccines in Finland. Vaccine (2009) 0.89
Legionella pneumophila serogroup 1 antibody kinetics in patients with Legionnaires' disease: implications for serological diagnosis. Scand J Infect Dis (2003) 0.88
Gene polymorphism in toll-like receptor 4: effect on antibody production and persistence after acellular pertussis vaccination during adolescence. J Infect Dis (2012) 0.88
Changes of the Swedish Bordetella pertussis population in incidence peaks during an acellular pertussis vaccine period between 1997 and 2004. APMIS (2007) 0.88
Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model. Vaccine (2005) 0.88
Pertussis immunization in the global pertussis initiative European region: recommended strategies and implementation considerations. Pediatr Infect Dis J (2005) 0.88
EUVAC.NET collaborative study: evaluation and standardisation of serology for diagnosis of pertussis. J Immunol Methods (2011) 0.87
Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection. Vaccine (2012) 0.87
Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J (2002) 0.87
Interactions between Bordetella pertussis and the complement inhibitor factor H. Mol Immunol (2010) 0.87
Toll-like receptor 3 L412F polymorphisms in infants with bronchiolitis and postbronchiolitis wheezing. Pediatr Infect Dis J (2012) 0.86
Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009. J Clin Microbiol (2012) 0.86
The association of genetic variants in toll-like receptor 2 subfamily with allergy and asthma after hospitalization for bronchiolitis in infancy. Pediatr Infect Dis J (2014) 0.86
PFGE and pertactin gene sequencing suggest limited genetic variability within the Finnish Bordetella parapertussis population. J Med Microbiol (2003) 0.85
Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin. Scand J Infect Dis (2008) 0.85
Clinical response to antibiotic therapy for community-acquired pneumonia. Eur J Pediatr (2004) 0.84
Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine (2004) 0.83
Recurrent antibiotic use in a small child and the effects on the family. Scand J Prim Health Care (2004) 0.83
Appearance of macrolide-resistant Bordetella pertussis strains in China. Antimicrob Agents Chemother (2013) 0.83
Pertussis vaccines: where to now? Expert Rev Vaccines (2011) 0.82
C4A deficiency in children and adolescents with recurrent respiratory infections. Hum Immunol (2012) 0.82
Infantile pertussis rediscovered in China. Emerg Infect Dis (2002) 0.82